DIO

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Rimonabant, NSCLC, Food, Biomarker, Doctor of Philosophy, CB1, Breast cancer, University of Virginia Cancer Center, SITC, The Obesity Society, Head, CSPC, FACP, Human, Therapeutic index, Cleavage, Yale School of Medicine, Society for Immunotherapy of Cancer, Mouse, DIO, Immunotherapy, University, Hand, Investment, Patient, Monoclonal antibody, Food and Drug Administration Amendments Act of 2007, Plasma, Conference, Liraglutide, Development, ADC, Brain, Insulin resistance, Society, AACR, IND, Manuscript, Poster, MMAE, Semaglutide, Tumor microenvironment, Carcinoma, Mab, Neck, Medical imaging, Vaccine, Soft drink, Pharmaceutical industry, Corbus, MD, Obesity

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.

The Hackett Group: U.S. Companies See Worsening Performance Of Payables, Collections and Inventory in Q2 2023

Retrieved on: 
Thursday, November 2, 2023
Professional Services, Business, Data Analytics, Other Professional Services, Finance, Consulting, Element, Textile, Tax, Biotechnology, Public expenditure, EBITDA, Research, Hackett, DSO, DIO, DPO, Depreciation

Rising inventories for utility and semiconductor and equipment companies played a major role in the degraded inventory performance.

Key Points: 
  • Rising inventories for utility and semiconductor and equipment companies played a major role in the degraded inventory performance.
  • An analysis of data from 1,000 of the largest U.S. public companies by The Hackett Group® comparing performance in Q2 2023 with Q2 2022 found the most significant decline in days inventory outstanding (DIO), which deteriorated by 7.1% (from 47.2 to 50.5 days).
  • Oil and gas, telecommunication equipment, utilities, and recreational products showed the greatest degradation in inventory performance.
  • The Q2 2023 Working Capital Survey update is produced by The Hackett Group’s Working Capital Management Solutions practice.

Key Core of the AMR: Cincoze P1201 Slim Embedded Computer

Retrieved on: 
Tuesday, October 24, 2023
Technology, Semiconductor, Engineering, Automotive Manufacturing, Aerospace, Manufacturing, Hardware, Robotics, Artificial Intelligence, Power over Ethernet, Mini, Vibration, LAN, Temperature, M.2, TDP, Certification, Wi-Fi, AMR, UL, USB, Hertz, Multimedia, COM, DIO, USB 3.2, EN, Safety, Communication, EMC, Mobile phone, Video game, Goldmont

This reduces personnel risks and ensures continuous and uninterrupted operation, significantly improving efficiency and reducing labor costs.

Key Points: 
  • This reduces personnel risks and ensures continuous and uninterrupted operation, significantly improving efficiency and reducing labor costs.
  • The Cincoze P1201 slim embedded computer, with its compact size, excellent performance, and rich I/O, has become the preferred core computer for AMR applications and has become a highly sought-after AMR exclusive model in the AMR market within just half a year of its launch.
  • View the full release here: https://www.businesswire.com/news/home/20231024351482/en/
    As a slim embedded computer, the P1201 has a compact size of only 204.5 x 149 x 41.5 mm, making it ideal for installation in the limited space in an AMR.
  • This ensures the P1201 meets high-level industrial-grade protection standards, guaranteeing safe and reliable operation in extreme conditions.

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Retrieved on: 
Tuesday, October 17, 2023
DIO, Partnership, Plasma, Morning Star, Rimonabant, Insulin resistance, Manuscript, Human, Weight loss, CB1, Mouse, The Obesity Society, Conference, Dietary supplement, Pharmaceutical industry, Tirzepatide, Semaglutide, Obesity, Liraglutide

“These data point to the potential of CRB-913, both as a monotherapy in combination with incretin therapies,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “These data point to the potential of CRB-913, both as a monotherapy in combination with incretin therapies,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • CRB-913 demonstrated markedly enhanced plasma exposure and markedly reduced brain levels compared to the first generation CB1 inverse agonist rimonabant.
  • Concomitantly, improvements were observed in body fat content, leptinemia, insulin resistance, liver triglycerides, liver fat deposits and liver histology.
  • Investigators concluded that CRB-913, in combination with incretin analogs, could potentially deliver meaningful improvements in obesity and related conditions.

Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023

Retrieved on: 
Monday, October 16, 2023
DIO, Pharmacokinetics, Obesity, Biology, Weight loss, Liver, Diabetes, DSM-IV codes, Safety, Administration, Human, Anpartsselskab, SC, Fasting, Lipid metabolism, Mouse, Phase 1, Glycated hemoglobin, Quality of life, Pharmaceutical industry

COPENHAGEN, Denmark, Oct. 16, 2023 /PRNewswire/ -- Cytoki Pharma, ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of medicines that harness IL-22 biology to drive improved outcomes for metabolic disease, today presented preclinical data demonstrating the potential of lipidated IL-22 to induce weight loss and positively impact a range of cardiometabolic risk factors at ObesityWeek 2023, held October 14-17 in Dallas.

Key Points: 
  • IL-22 is an atypical, non-immunomodulatory cytokine, which selectively targets epithelial tissues, including those that play important roles in metabolic processes, such as the gut and liver.
  • Cytoki's lipidated IL-22 analogues leverage this innate biology and offer first-in-class potential to address a range of metabolic diseases, including obesity and type 2 diabetes.
  • Subsequent studies in diabetic db/db mice indicate that treatment with lipidated IL-22 normalized blood glucose levels and reduced HbA1c levels independent of food intake, accompanied by dose-dependent insulin sensitization.
  • The presentation details are as follows:
    Location: Kay Bailey Hutchinson Convention Center, Room D174

Fractyl Health Demonstrated Significant Improvement in Weight Loss in Head-to-Head Preclinical Obesity Studies of its Rejuva® GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Compared to Chronic Semaglutide at EASD’s Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023
Biotechnology, Diabetes, Health, General Health, Pharmaceutical, Other Science, Medical Devices, Research, Genetics, Science, Clinical Trials, DSM-IV codes, Obesity, Therapy, Gene, Type 2 diabetes, Weight loss, Pancreas, European Association for the Study of Diabetes, EASD, DIO, Annual general meeting, T2D, Pharmaceutical industry, Vaccine

During the oral presentation today, the company presented late-breaking results from an additional, second efficacy model of metabolic disease, the well-validated DIO rodent model of obesity.

Key Points: 
  • During the oral presentation today, the company presented late-breaking results from an additional, second efficacy model of metabolic disease, the well-validated DIO rodent model of obesity.
  • A single dose of a GLP-1 PGTx was compared to chronic semaglutide 10 nmol/kg/day in a head-to-head study.
  • GLP-1 PGTx demonstrated improved weight loss compared to semaglutide at day 15, with 24.8% weight loss for GLP-1 PGTx vs. 18.4% weight loss for semaglutide (p
  • Both semaglutide and GLP-1 PGTx treatment arms saw reduced food intake compared to vehicles that persisted through day 15, providing a mechanistic explanation for the weight loss in these animals.

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

Retrieved on: 
Thursday, September 28, 2023
HD, GSK, DSM-IV codes, Human, Obesity, Duchenne muscular dystrophy, Therapy, Genetics, Serum, Deep learning, Novel, Weight loss, Wave, Mutation, MBA, Part, RNA, Biomarker, Doctor of Philosophy, CNS, Messenger, Chemistry, Odds ratio, Protein, DIO, DMD, MD, Pizzicato, Patient, Map, Kidney, Webcast, Mouse, Liver, Exon, RNA editing, Vaccine, Pharmaceutical industry, Soft drink, Dietary supplement, Duchenne, Small RNA, AATD

“We are bringing an exciting, genetics-based approach to the metabolic disease and obesity space with our first siRNA program targeting INHBE.

Key Points: 
  • “We are bringing an exciting, genetics-based approach to the metabolic disease and obesity space with our first siRNA program targeting INHBE.
  • In addition to high-impact silencing targets like INHBE, we have a near-term pipeline focus on protein restoration and repair with our RNA editing and splicing capabilities.
  • Growing pipeline with high-value RNA editing targets:
    Beyond WVE-006, Wave highlighted several undisclosed RNA editing targets which span prevalent and rare liver, kidney and lung diseases.
  • The multidose portion of the SELECT-HD clinical trial is ongoing and has been enrolling with high demand.

Hackett: Largest U.S. Cos Hit a Ceiling on Delaying Supplier Payments; Payables Challenges Drive Worsening of Working Capital Performance

Retrieved on: 
Tuesday, June 27, 2023
Finance, Consulting, Accounting, Professional Services, Other Professional Services, Hackett, Semiconductor, Disclosure, Tax, DPO, Financial Accounting Standards Board, Overalls, DSO, Research, CCC, Vehicle registration plates of Nepal, Recreation, EBITDA, DIO, Restaurant, Depreciation, Growth, FASB, Cryptocurrency, Life insurance, Online shopping, Bank

The Hackett Group’s 2023 Working Capital Survey is currently featured on CFO.com .

Key Points: 
  • The Hackett Group’s 2023 Working Capital Survey is currently featured on CFO.com .
  • Industries where companies saw the greatest degradation of working capital performance included: motor vehicles; semiconductors and equipment; computer hardware and peripherals; and household and personal care.
  • For a decade or more, this practice has been the easiest way for companies to improve their working capital performance, and companies have heavily relied on it.
  • “ Cash flow management should be a top priority on the corporate agenda to provide liquidity for strategic investments.”

Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model

Retrieved on: 
Saturday, June 24, 2023
Type 2 diabetes, Obesity, Connective tissue, Diabetes, Semaglutide, Weight loss, Diet-induced obesity model, Type 2, Blood, Animal, Metabolism, DSM-IV codes, Patient, DIO, American Diabetes Association, Mouse, Paper, Entrepreneurship, PTP1B, ADA, Human, Pharmacology, Pharmaceutical industry, Dietary supplement

The data were presented at the American Diabetes Association’s (ADA) 83rd Scientific Sessions in San Diego.

Key Points: 
  • The data were presented at the American Diabetes Association’s (ADA) 83rd Scientific Sessions in San Diego.
  • In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function.
  • The study presented today compared the effects of subcutaneously administered ENT-03 to semaglutide on blood glucose, adiposity, and body weight over a 10-week treatment period in a diet-induced obesity (DIO) mouse model.
  • Weight loss continues smoothly in the ENT-03 treatment group over the 10-week period, plateauing at lean body weight, and blood glucose remains in the normoglycemic range.

Cincoze releases the high-performance & compact embedded computer DX-1200 for industrial automation

Retrieved on: 
Thursday, May 4, 2023
Technology, Hardware, Consumer Electronics, IOT (Internet of Things), ECC, Mini, Failure, Rugged, GNSS, LAN, Vibration, Xe, Wi-Fi, Temperature, Multimedia, EMC, DDR5, Certification, Comet, COM, DIO, Automation, Risk, Intel, EN, Bluetooth, AI, ESD, GPU, Safety, UHD, Video game

Rugged embedded computing brand - Cincoze, recently launched the DX-1200 embedded computer, the latest addition to its Rugged Computing - DIAMOND product line.

Key Points: 
  • Rugged embedded computing brand - Cincoze, recently launched the DX-1200 embedded computer, the latest addition to its Rugged Computing - DIAMOND product line.
  • Featuring a compact and high-performance design, the DX-1200 overcomes space limitations while retaining extreme capability.
  • The DX-1200 inherits the same rugged features that underscore the DIAMOND product line, such as wide temperature and voltage support, and vibration and shock resistance.
  • The DX-1200 has become the best solution for industrial automation with its rich certification, rugged design, and stable performance.